EUVIMEDPoznaj EUVIMED
Open access · CC BY 4.0

Overexpression of m 7 G writers METTL1 and BUD23 confers oncogenicity in kidney renal clear cell carcinoma

Anni Su, Jessica Tieng, Xueying S Xu, Richard P Tan, Yuchen Feng, Justin J-L Wong iD

The Journal of Pathology · 2025-09 · 267 (1) · 1-9

DOI: 10.1002/path.6453 ↗

At a glance

Journal article in The Journal of Pathology, published online on 2025-07-18. Written by Anni Su and 5 co-authors. Institution: Epigenetics and RNA Biology Laboratory, Charles Perkins Centre, University of Sydney, Camperdown, Australia. Major MEDLINE topics: Carcinoma, Renal Cell, Kidney Neoplasms, Methyltransferases. Cited 3 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY 4.0). Funded by: NSW Health, National Health and Medical Research Council.

AbstraktSubjectsDane bibliograficzneCiteRelated studies

Abstract (original language)

Emerging evidence shows that N7‐methylguanosine (m 7 G) modification and its writers contribute to the development of diverse cancers. However, the role of m 7 G writers in kidney renal clear cell carcinoma (KIRC) remains unclear. In this study we show that the catalytic components of m 7 G writers, METTL1 and BUD23, are overexpressed in advanced KIRC and are associated with worse overall survival. Knockdown of METTL1 or BUD23 inhibited cell proliferation, colony formation, and migration in KIRC cell lines, indicating their oncogenic role in KIRC. Furthermore, we observed that METTL1 and BUD23 expression was negatively correlated with the expression of key tumor suppressor genes commonly dysregulated in KIRC. We observed METTL1‐mediated m 7 G methylation in mRNAs expressed by these tumor suppressor genes, indicating that METTL1 may regulate these genes via m 7 G modification. Overall, our study highlights the oncogenic role of METTL1 and BUD23 in KIRC and their potential as prognostic biomarkers and therapeutic targets in KIRC. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsMethyltransferasesHumansGene Expression Regulation, NeoplasticCell ProliferationCell Line, TumorMaleFemaleCell MovementBiomarkers, TumorMiddle Aged

Author keywords

BUD23METTL1RNA modificationkidney cancerm7G methylationoncogenetumor suppressor gene

Substances

MethyltransferasesMETTL1 protein, humanBiomarkers, Tumor

Authors and institutions

  • Epigenetics and RNA Biology Laboratory, Charles Perkins Centre, University of Sydney, Camperdown, Australia.
  • School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Camperdown, Australia.

ORCID profiles: Justin J-L Wong

Funding

  • NSW Health
  • National Health and Medical Research Council

Cite

APA

Su, A., Tieng, J., Xu, X. S., Tan, R. P., Feng, Y., & Wong, J. J. (2025). Overexpression of m 7 G writers METTL1 and BUD23 confers oncogenicity in kidney renal clear cell carcinoma. The Journal of Pathology, 267(1), 1-9. https://doi.org/10.1002/path.6453

Vancouver

Su A, Tieng J, Xu XS, Tan RP, Feng Y, Wong JJ. Overexpression of m 7 G writers METTL1 and BUD23 confers oncogenicity in kidney renal clear cell carcinoma. The Journal of Pathology. 2025;267(1):1-9. doi:10.1002/path.6453

BibTeX
@article{Su2025,
  author = {Su, Anni and Tieng, Jessica and Xu, Xueying S and Tan, Richard P and Feng, Yuchen and Wong, Justin J-L},
  title = {Overexpression of m 7 G writers METTL1 and BUD23 confers oncogenicity in kidney renal clear cell carcinoma},
  journal = {The Journal of Pathology},
  year = {2025},
  volume = {267},
  number = {1},
  pages = {1--9},
  doi = {10.1002/path.6453}
}
Start for free →